期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

国产多西他赛联合顺铂治疗晚期乳腺癌和非小细胞肺癌的随机对照研究 被引量：2

Efficacy and tolerance of two generic versions of docetaxel in combination with cisplatin in treatment of advanced breast cancer and non-small cell lung cancer:A comparative study
在线阅读 下载PDF
导出
摘要 目的评价多西他赛注射液(辽宁省药业有限公司)与对照药物(已上市国产多西他赛)的临床疗效和不良反应,比较两者联合顺铂治疗晚期乳腺癌及非小细胞肺癌的临床疗效和安全性。方法晚期和(或)转移性乳腺癌患者或非小细胞癌患者以1:1的比例随机分配至多西他赛75mg/m2+顺铂90mg/m2研究组或对照药物75mg/m2+顺铂90mg/m2对照组,21天为1周期,2周期后评价疗效,未进展的病例继续治疗至4周期。结果134例患者中120例可评价疗效,134例可评价不良反应。非小细胞肺癌有效率多西他赛研究组14.7、对照药组11.5;乳腺癌有效率多西他赛研究组27.6、对照药组32.3;各组间有效率差异均无统计学意义。不良反应主要为骨髓抑制、恶心、呕吐、脱发。多西他赛与对照药物比较,疗效和不良反应相似。结论多西他赛联合顺铂方案治疗乳腺癌和非小细胞肺癌安全有效,耐受性好,与对照药物疗效和不良反应相似。 Objective To evaluate the efficacy and safety of docetaxel （Liaoning Pharmaceutical Company, Ltd） in patients with advanced breast cancer or non-small cell lung cancer. Methods Patients with advanced breast cancer were randomly assigned to receive docetaxel （Liaoning Pharmaceutical Company,Ltd） 75 mg/m^2iv plus cisplatin 90 mg/m^2（Group A） every 3 weeks or docetaxel （domestic generic product on the markets） 75 mg/m^2 iv plus cisplatin 90 mg/m^2 iv every 3 weeks （Group B）. Patients with advanced non-small cell lung cancer were also randomly assigned to regimens of docetaxel （Liaoning Pharmaceutical Company,Ltd） plus cisplatin （Group C） and docetaxel （domestic product on the markets） plus cisplatin（Group D）. Patients were treated for four treatment cycles or until progressive disease,death,or intolerable toxicity occur. Results 120 of 134 patients were evaluable for efficacy,and all patients evaluable for side effects. Overall response rates of Group A, B,C, D were 27. 6%32. 3%,14. 7% ,and 11. 5%,respectively. There was no statistically significant difference in overall response rate between Group A and B, or C and D. The major side effects were myelosuppression, nausea,vomiting,and alopecia. Conclusion The docetaxel （Liaoning Pharmaceutical Company,Ltd） has similar efficacy with docetaxel （domestic product on the markets）,and good tolerance.
作者 何小慧 石远凯 杨晟 刘基巍 高亚杰 李凯 王华庆 冯威健 高雅苓 韩少梅
机构地区 中国医学科学院北京协和医学院肿瘤医院肿瘤研究所 大连医科大学附属第一医院 天津市肿瘤医院 北京世纪坛医院 辽宁省肿瘤医院 中国医学科学院北京协和医学院基础医学研究所
出处 《实用肿瘤杂志》 CAS 2008年第6期524-528,共5页 Journal of Practical Oncology
关键词 乳腺肿瘤/药物疗法 顺铂/投药和剂量 癌 非小细胞肺/药物疗法 紫杉酚/投药和剂量 抗肿瘤联合化疗方案/治疗应用 breast neoplasms/drug therapy cisplatin/administration ＆ dosage carcinoma, non-small cell lung/drug therapy paclitaxel/administration dosage antineoplastic cornbined chemotherapy protocols/therapeutic use
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献21

  • 1Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer [J]. N Engl J Med,2002,346(2):92-98.
  • 2Crown J. Docetaxel: overview of an active drug for breast cancer [J]. Oncologist, 2001,6 (Suppl 3) : 1 - 4.
  • 3Chevallier B,Fumoleau P,Kerbrat P,et al. Docetaxei is a major cytotoxic drug for the treatment of advanced breast cancer: a phase Ⅱ trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer [J]. J Clin Oncol,1995,13(2):314-322.
  • 4Hudis CA,Seidman AD,Crown JP,et al. Phase Ⅱ and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer [J]. J Clin Oncol, 1996,14(1) :58-65.
  • 5Ravdin PM,Burris HA,3rd,Cook G,et al. Phase trial of docetaxel in advanced anthraeycline-resistant or anthracenedione-resistant breast cancer [J]. J Clin OncoI,1995,13(12):2879-2885.
  • 6Trudeau ME, Eisenhauer EA, Higgins BP, et al. Docetaxel in patients with metastatic breast cancer: a phase Ⅱ study of the National Cancer Institute of Canada Clinical Trials Group [J]. J Clin Oncol1,1996, 14(2):422-428.
  • 7Valero V, Holmes FA, Waiters RS, et al. Phase trial of docetaxel : a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer [J]. JClin Oncol,1995,13(12):2886-2894.
  • 8Valero V, Jones SE,Von Hoff DD,et al. A phase Ⅱ study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer [J]. J Clin Oncol, 1998, 16 (10) : 3362- 3368.
  • 9Crown JP. The platinum agents: a role in breast cancer treatment [J]? Semin Oncol,2001,28(1 Suppl 3) :28-37.
  • 10Zoli W, Flamigni A, Frassineti GL, et al. In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers [J]. Breast Cancer Res Treat, 1995,34(1):63-69.

二级参考文献10

  • 1DECATRIS MP, SUNDAR S, O'BYME KJ. Platinum-based chemotherapy in metastatic breast cancer: current status [J]. Cancer Treat Rev, 2004, 30(1):53 - 81.
  • 2KARIYA S, OQAWA Y, NISHIOKA A, et al. Docetaxel -cisplatin combined chemotherapy in Japanese patients with anthracycline-pretreated advanced breast cancer [J]. Oncol Rep, 2002, 9 (6) :1345 - 1349.
  • 3ROSATI G, RICCARDI F, TUCCI A, et al. A phase Ⅱ study of paclitaxel/cisplatin combination in patients with metastatic breast cancer refractory to anthracycline - based chemotherapy [J].Tamori,2000,86(3):207 - 210.
  • 4SPARANO JA, NEUBERQ D, GLICK JH, et al. Phase Ⅱ trim of biweekly paclitaxel and cisplatin in advanced breast carcinoma: an Eastern Cooperative Oncology Group study [J]. J Clin Oncol,1997, 15(5) :1880 - 1884.
  • 5TSU JI N, FURUSE K, ASANUMA K, et al. Mutations of the p53 gene and loss of heterozygosity at chromosome 17p13.1 are associated with increased survivin expression in breast cancer [J].Breast Cancer Res Treat, 2004, 87(1):23 - 31.
  • 6DALES JP, GARCIA S, ANDRAC L, et al. Prognostic significance of angiogenes is evaluated by CD105 expression compared to CD31 in 905 breast carcinomas: correlation with long-term patient outcome[J]. lnt J Ottcol, 2004, 24(5) :1197 - 1204.
  • 7徐兵河,袁芃,李青,张频,赵龙妹,周际昌.去甲长春花碱联合顺铂治疗晚期乳腺癌的临床疗效[J].中华肿瘤杂志,2001,23(6):521-522. 被引量：50
  • 8袁芃,徐兵河,李青,张频,赵龙妹.去甲长春花碱为主方案治疗蒽环类药物耐药性晚期乳腺癌的疗效[J].中国肿瘤临床,2001,28(8):602-604. 被引量：15
  • 9林显敢,谢德荣,姚和瑞,李志花,江志敏,刘天浩.环磷酰胺、阿霉素、5-氟尿嘧啶方案与紫杉醇、顺铂方案治疗晚期乳腺癌的疗效比较[J].癌症,2003,22(4):411-414. 被引量：16
  • 10徐兵河,李凯,刘端琪,李文辉,认宏轩.吉西他滨联合顺铂治疗50例蒽环类耐药性晚期乳腺癌[J].中国癌症杂志,2003,13(6):579-581. 被引量：57

共引文献45

同被引文献13

  • 1郝澄澄,刘慧忠,王俊超,王湘连,田光亮.三维适形放疗加紫杉醇卡铂周方案同步治疗Ⅲ期非小细胞肺癌的疗效观察[J].山东大学学报（医学版）,2009,47(2):42-45. 被引量：3
  • 2Fournel P, Robinet G, Thomas P, et al. Randomized phase Ⅲ trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study [J].J Clin Oncol,2005,23(25) :5910-5917.
  • 3Heim W, Wampler GL, Lokich J J, et al. A study of infusional cisplatin and infusional fluorouracil for locally advanced or metastatic non-small cell lung cancer :a Mid-Atlantic Oncology Program Study[J].J Clin Oncol, 1991,9 (12) : 2162- 2166.
  • 4Itoh Y, Fuwa N, Matumoto A, et at. Continuous infusion low-dose CDDP/5-FU plus radiation in inoperable or recurrent non-small cell lung cancer: preliminary experience[J]. Am J Clin Oncol, 2002,25 (3) :230-234.
  • 5Segawa Y,Ueoka H,Kiura K,et al. A phase Ⅱ study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group [J]. Br J Cancer,2000,82(1):104-111.
  • 6Margaritora S, Cesario A, Galetta D, et al. Ten year experience with induction therapy in locally advanced non-small cell lung cancer (NSCLC): is clinical restaging predictive of pathological staging[J]? Eur J Cardiothorac Surg, 2001,19(6):894-898.
  • 7Albain KS, Crowley J J, Turrisi AT, et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage Ⅲ8 non-small cell lung cancer: a Southwest Oncology Group phase Ⅱ study, SWOG 9019 [J]. J Clin Oncol, 2002,20(16), 3454- 3460.
  • 8申文江,王绿化.放疗损伤[M].北京:中国医药科技出版社,2001:256-260.
  • 9Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009 [J]. CA Cancer J Clin,2009,59(4):225-249.
  • 10莫伟强,吴健乾,陆启光,姜轶飞.多西紫杉醇联合顺铂与长春瑞宾联合顺铂治疗晚期非小细胞肺癌的临床研究比较[J].实用肿瘤杂志,2008,23(4):369-371. 被引量：3

引证文献2

二级引证文献10

实用肿瘤杂志
2008年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部